Proactive Adalimumab Monitoring in Inflammatory Bowel Disease: Current Data and Future Perspectives

Eitemau Tebyg

• Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease
  gan: Papamichael, Konstantinos, et al.
  Cyhoeddwyd: (2019)
• Maintenance adalimumab concentrations are associated with biochemical, endoscopic and histologic remission in inflammatory bowel disease
  gan: Juncadella, Anna, et al.
  Cyhoeddwyd: (2018)
• Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease
  gan: Papamichael, Konstantinos, et al.
  Cyhoeddwyd: (2018)
• Comparison between assays used for therapeutic drug monitoring of infliximab and adalimumab in inflammatory bowel disease
  gan: Papamichael, Konstantinos, et al.
  Cyhoeddwyd: (2020)
• Improved Long-Term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab
  gan: Papamichael, Konstantinos, et al.
  Cyhoeddwyd: (2017)